The value and utility of MRD in the management of adults with newly-diagnosed AML

This podcast features experts Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, who debate the value and utility of measurable residual disease (MRD) in the management of adults with newly-diagnosed acute myeloid leukemia (AML). The discussion explores current limitations of MRD assays, the challenges of standardization, and the importance of integrating multiple modalities. This took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.